Business News

    Healius (ASX:HLS) reveals Directors' Statement on Australian Clinical Labs' takeover

    Article Image

    Healius (ASX:HLS) has announced concerns to Australian Clinical Lab's (ACL) off-market takeover bid of a share exchange ratio of 0.74 ACL shares for every one Healius share, which is a discount of 4.2% to the price the day before the offer. 

    The Australian healthcare company noted some of the offer's deficiencies, including overly restrictive conditions and a lack of control premium.

    Healius' largest shareholder, Perpetual Investment Management, called the proposal unattractive and unfavourable for Healius' shareholders, while Tanarra Capital stated ACL could not achieve 90% ownership.

    Healius' board will consider future merger proposals but reiterated its "take no action" advice regarding ACL's offer.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa